Marketing: Page 13
-
Amarin turns to job cuts as generics challenge its heart pill
Facing greater competition and declining sales in the U.S., the drugmaker is laying off about 40% of its workforce as part of an effort to save $100 million over the next year.
By Jacob Bell • June 6, 2022 -
Courtesy of Regeneron Pharmaceuticals
Regeneron buys control of cancer drug Libtayo from Sanofi
The biotech, which has been partnered with Sanofi for years, will pay $900 million upfront to gain sole control of the cancer immunotherapy.
By Jonathan Gardner • Updated June 2, 2022 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineCommercialization
New drugs for obesity are becoming blockbusters, while Trump administration pressure is reshaping pharma marketing strategies ahead of looming patent cliffs.
By BioPharma Dive staff -
Maddie Meyer via Getty Images
Moderna vaccine sales surpass expectations as company looks to fall boosters
The trajectory of COVID-19 vaccine sales is now harder to predict amid questions about the rollout of additional doses and whether purchasing in the U.S. might shift from the federal government to private payers.
By Ned Pagliarulo • May 4, 2022 -
Permission granted by Bristol-Myers Squibb
Bristol Myers wins FDA approval for first drug to treat inherited heart condition
Bristol Myers paid $13 billion to acquire the drug's maker, MyoKardia, and expects it to become a blockbuster. But a tricky dosing regimen, as well as safety concerns, could challenge the pharmaceutical giant's lofty forecast.
By Jonathan Gardner • April 28, 2022 -
Permission granted by Biogen
Biogen pulls European application for Aduhelm in another setback for the Alzheimer's drug
In a letter to regulators, Biogen said it chose to withdraw its approval filing after discussions with the EMA, which previously found the data supporting Aduhelm to be lacking.
By Jacob Bell , Ned Pagliarulo • April 22, 2022 -
Getty Images
DOJ cracks down on 'largest and most wide-ranging' COVID-19 fraud
Defendants, including doctors, medical business executives and fake vaccination card manufacturers, caused nearly $150 million in false billings to federal programs, the DOJ said.
By Rebecca Pifer Parduhn • April 21, 2022 -
Permission granted by GoodRx
Sponsored by GoodRxInflation is forcing prioritization of healthcare spending — are you ready?
Inflation means your customers' money doesn't travel as far as it did a few weeks ago.
April 18, 2022 -
Permission granted by Akili Interactive
Deep DiveCan digital therapeutics be profitable?
Licensing deals with pharmaceutical companies were an early strategy for digital health companies, but not all of them have lasted.
By Elise Reuter • April 11, 2022 -
adobe.com/Tierney
Sponsored by Acceleration PointThe power of alerts
As medical affairs continues to invest in systems and data, it can quickly become overwhelming to keep up with it all.
April 11, 2022 -
Medicare finalizes policy limiting coverage of Biogen Alzheimer's drug
Biogen said it is considering its options following CMS' decision, which restricts reimbursement of Aduhelm to patients enrolled in a randomized clinical trial.
By Jonathan Gardner • Updated April 7, 2022 -
Fizkes/Shutterstock.com
Sponsored by OM1A new approach for post-marketing safety studies
The large quantity of digitized healthcare data in the U.S. presents an enormous opportunity to shift dramatically how post-marketing safety studies can and should be conducted.
By Stefan Weiss, MD, MHSc, MBA, Managing Director of Dermatology, OM1 • April 4, 2022 -
Deep Dive // Patent thickets
Two decades and $200 billion: AbbVie’s Humira monopoly nears its end
The first biosimilar copy of Humira is set to arrive in the U.S. next week, testing both AbbVie and the market potential for knockoff biologic drugs.
By Jonathan Gardner • Updated Jan. 27, 2023 -
Permission granted by Akili Interactive
Akili, with plans to go public, prepares to ramp up marketing of video game treatment
"We've proven that foundation and now it's time to run and scale," said CEO Eddie Martucci. The company is going public through a $1 billion SPAC, rather than a traditional IPO.
By Elise Reuter • March 10, 2022 -
AbbVie holds off another Humira challenger with Alvotech deal
A settlement will allow the Iceland-based drugmaker to launch its Humira copycat, currently under FDA review, in the U.S. beginning next July.
By Ned Pagliarulo • March 9, 2022 -
Novo sees fast growth ahead of obesity drugs despite production hurdles
The Danish drugmaker aims to triple sales of its weight loss treatments Wegovy and Saxenda by 2025. But first, Novo needs to resolve manufacturing constraints that have slowed the former drug's launch.
By Ned Pagliarulo • March 4, 2022 -
Permission granted by DarioHealth
Sanofi partners with digital health company DarioHealth
The deal with DarioHealth is one of several digital health investments by the French pharma company in recent years, although not all have panned out.
By Elise Reuter • March 2, 2022 -
Getty Images
Moderna sued for allegedly infringing patents tied to COVID-19 vaccine
Arbutus and partner Genevant claim Moderna's coronavirus shot uses delivery technology covered by six patents they hold, an allegation Moderna denies.
By Ned Pagliarulo • Feb. 28, 2022 -
Retrieved from FTC.
FTC deadlocks on vote to launch study into PBM practices
The antitrust agency won't study pharmacy benefit managers' pricing and contract practices as proposed, after a 2-2 vote by commissioners Thursday.
By Samantha Liss • Feb. 17, 2022 -
Seagen shares sink as sales outlook of cancer drug disappoints
The biotech is predicting sales of Tukysa, its new breast cancer drug, will remain flat or fall in 2022 as competition increases from AstraZeneca's rival medicine Enhertu.
By Jacob Bell • Feb. 10, 2022 -
Amgen expects rising sales through 2030, but Wall Street still has doubts
Facing falling sales of top-seller Enbrel, the biotech tried to shore up confidence in its ability to grow new products, like the cancer drug Lumakras.
By Kristin Jensen • Feb. 9, 2022 -
Permission granted by Biogen
Biogen buys into fast-advancing Roche cancer drug
The biotech will pay $30 million to opt into rights for mosunetuzumab, a bispecific antibody that Roche has developed for non-Hodgkin's lymphoma.
By Ned Pagliarulo • Feb. 1, 2022 -
Permission granted by Biogen
Medicare faces blowback over plan to limit coverage of Biogen's Alzheimer's drug
Biogen, along with allies in industry, plans to pressure Medicare to water down its policy, which limits coverage of Aduhelm and drugs like it to clinical trials.
By Jonathan Gardner , Jacob Bell • Jan. 14, 2022 -
Permission granted by Biogen
Medicare proposes to limit coverage of Biogen Alzheimer's drug
The program will only cover Aduhelm, which the FDA controversially approved last June, for patients enrolled in rigorous clinical trials, likely forestalling broader adoption of the treatment.
By Jonathan Gardner , Jacob Bell • Updated Jan. 11, 2022 -
Permission granted by Novartis
Novartis wins FDA approval for new heart drug, but faces uphill sales battle
Leqvio, which Novartis acquired for nearly $10 billion two years ago, arrives with high sales expectations. But uptake could be slow as insurers and doctors weigh the drug's safety and cost-effectiveness.
By Jonathan Gardner • Dec. 22, 2021 -
Permission granted by Biogen
New Alzheimer's drugs
After intense pushback, Biogen to cut price of Alzheimer's drug
Effective Jan. 1, the average list price for Aduhelm will drop about 50% to just over $28,000 a year. It's a move the company hopes will appease insurers and lower out-of-pocket costs for patients.
By Jacob Bell • Dec. 20, 2021
Previous
